Market Exclusive

Analyst Activity – BMO Capital Markets Raises Its Price Target On Alexion Pharmaceuticals (NASDAQ:ALXN) to $168.00

Analyst Ratings For Alexion Pharmaceuticals (NASDAQ:ALXN)

Today, BMO Capital Markets raised its price target on Alexion Pharmaceuticals (NASDAQ:ALXN) to $168.00 per share.

There are 5 hold ratings, 17 buy ratings, 1 strong buy rating on the stock.

The current consensus rating on Alexion Pharmaceuticals (NASDAQ:ALXN) is Buy (Score: 2.83) with a consensus target price of $158.05 per share, a potential 14.53% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Alexion Pharmaceuticals (NASDAQ:ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) has insider ownership of 4.35% and institutional ownership of 94.84%.

Recent Trading Activity for Alexion Pharmaceuticals (NASDAQ:ALXN)
Shares of Alexion Pharmaceuticals closed the previous trading session at 137.99 up +4.07 3.04% with 2,423,425 shares trading hands.

Exit mobile version